A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 19, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q1 FY2027, filed Nov 2, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CLX SEC filings page.
Clorox Company (CLX) reported $7.2B in revenue over the twelve months to Sep 30, 2026, up 6.3% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue is shrinking, while FY2026 balance-sheet expansion and heavier debt made cash conversion less forgiving.
Earnings quality remained relatively intact: operating cash flow was$612M against net income of$587M , so reported profit broadly became operating cash. After capital expenditures of$207M , free cash flow was$405M , showing that reinvestment absorbed the larger cash difference.
Gross economics weakened as revenue fell
Assets rose
Financial Health Signals
Scored against operating companies for FY2026. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Clorox Company's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Clorox Company scores 67/100 on it among other operating companies.
Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Clorox Company scores 22/100 on it among other operating companies.
Clorox Company carried $44.23 of long-term debt for every $1 of shareholders' equity at the end of fiscal year 2026, a debt-to-equity ratio of 44.23. With no EBITDA figure for fiscal year 2026, Clorox Company is ranked on that ratio rather than on net debt against EBITDA, a lower ratio being the safer one, and scores 1/100 among other operating companies measured the same way.
Clorox Company held $0.66 of current assets for every $1 of current liabilities at the end of fiscal year 2026, a current ratio of 0.66. Liquidity ranks operating companies on that ratio, and Clorox Company scores 8/100 among other operating companies.
Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. Clorox Company scores 57/100 on it among other operating companies.
Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Clorox Company scores 80/100 on it among other operating companies.
Clorox Company passes 4 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Clorox Company generates $1.04 in operating cash flow ($612.0M OCF vs $587.0M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Key Financial Metrics
Earnings & Revenue
Clorox Company generated $1.9B in revenue in Q1 2027. This represents an increase of 33.3% from the same quarter a year earlier. Against the prior quarter it is down 2.2%.
Clorox Company reported $170.0M in net income in Q1 2027. This represents an increase of 112.5% from the same quarter a year earlier. Against the prior quarter it is up 4.3%.
Clorox Company earned $1.39 per diluted share (EPS) in Q1 2027. This represents an increase of 113.8% from the same quarter a year earlier. Against the prior quarter it is up 3.7%.
Not reported for Q1 2027.
Cash & Balance Sheet
Clorox Company generated $105.0M in free cash flow in Q1 2027, representing cash available after capex. This represents an increase of 84.2% from the same quarter a year earlier. Against the prior quarter it is down 57.0%.
Clorox Company held $184.0M in cash against $4.0B in long-term debt as of Q1 2027.
Clorox Company paid $2.50 per share in dividends in Q1 2027. This represents an increase of 0.8% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Margins & Returns
Clorox Company's gross margin was 40.4% in Q1 2027, indicating the percentage of revenue retained after direct costs. This is down 1.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.9 percentage points.
Clorox Company's net profit margin was 8.9% in Q1 2027, showing the share of revenue converted to profit. This is up 3.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.6 percentage points.
Not reported for Q1 2027.
Not reported for Q1 2027.
Capital Allocation
Clorox Company invested $29.0M in research and development in Q1 2027. This represents an increase of 3.6% from the same quarter a year earlier. Against the prior quarter it is down 9.4%.
Clorox Company repurchased no shares in Q1 2027. This represents a decrease of 100.0% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Clorox Company invested $38.0M in capex in Q1 2027, funding long-term assets and infrastructure. This represents an increase of 5.6% from the same quarter a year earlier. Against the prior quarter it is down 55.8%.
CLX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.9B+33.3% | $1.9B-2.0% | $1.7B+0.1% | $1.7B-0.8% | $1.4B-18.9% | $2.0B+4.5% | $1.7B-8.0% | $1.7B-15.3% |
| Cost of Revenue | $1.1B+36.3% | $1.1B+7.5% | $948.0M+2.6% | $951.0M+0.3% | $833.0M-12.8% | $1.1B+4.4% | $924.0M-11.8% | $948.0M-15.7% |
| Gross Profit | $770.0M+29.2% | $804.0M-13.0% | $722.0M-3.0% | $722.0M-2.2% | $596.0M-26.1% | $924.0M+4.5% | $744.0M-2.9% | $738.0M-14.8% |
| R&D Expenses | $29.0M+3.6% | $32.0M0.0% | $27.0M0.0% | $29.0M-6.5% | $28.0M-9.7% | $32.0M-3.0% | $27.0M-15.6% | $31.0M-3.1% |
| SG&A Expenses | $290.0M+4.7% | $298.0M+0.7% | $229.0M-14.2% | $262.0M-6.4% | $277.0M-1.4% | $296.0M+10.4% | $267.0M-11.3% | $280.0M-13.0% |
| Interest Expense | $52.0M+126.1% | $55.0M+150.0% | $27.0M+17.4% | $25.0M+13.6% | $23.0M+9.5% | $22.0M+4.8% | $23.0M+4.5% | $22.0M-15.4% |
| Income Tax | $34.0M+36.0% | $46.0M-37.8% | $65.0M+3.2% | $54.0M+25.6% | $25.0M-66.2% | $74.0M+37.0% | $63.0M+687.5% | $43.0M+7.5% |
| Net Income | $170.0M+112.5% | $163.0M-50.9% | $187.0M+0.5% | $157.0M-18.7% | $80.0M-19.2% | $332.0M+53.7% | $186.0Mn/m | $193.0M+107.5% |
| EPS (Basic) | $1.39+113.8% | $1.34-50.2% | $1.54+2.0% | $1.29-16.8% | $0.65-18.8% | $2.69+54.6% | $1.51n/m | $1.55+106.7% |
| EPS (Diluted) | $1.39+113.8% | $1.34-50.0% | $1.54+2.7% | $1.29-16.2% | $0.65-18.8% | $2.68+54.9% | $1.50n/m | $1.54+105.3% |
| Diluted Shares (Avg) | 122M-0.8% | N/A | 122M-1.8% | 122M-2.2% | 123M-1.3% | N/A | 124M-0.1% | 125M0.0% |
Not reported in any period shown, so not listed: Operating Income, EBITDA.
CLX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $7.8B+41.7% | $7.8B+40.2% | $6.4B+16.8% | $5.6B+0.6% | $5.5B+0.6% | $5.6B-3.3% | $5.5B-5.0% | $5.6B-5.6% |
| Current Assets | $1.9B+13.9% | $1.8B+13.4% | $2.7B+66.7% | $1.7B+5.9% | $1.7B+7.6% | $1.6B-0.9% | $1.6B-4.3% | $1.6B-9.5% |
| Cash & Equivalents | $184.0M+10.8% | $143.0M-14.4% | $1.2B+425.2% | $227.0M-21.7% | $166.0M-40.3% | $167.0M-17.3% | $226.0M+3.2% | $290.0M-18.3% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Inventory | $774.0M+34.1% | $777.0M+48.6% | $588.0M-7.4% | $608.0M+2.7% | $577.0M-2.9% | $523.0M-17.9% | $635.0M-5.8% | $592.0M-9.6% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Goodwill | $1.9B+58.4% | $1.9B+58.3% | $1.2B+0.6% | $1.2B+1.0% | $1.2B-0.5% | $1.2B+0.1% | $1.2B-0.6% | $1.2B-2.6% |
| Total Liabilities | $7.7B+43.1% | $7.5B+48.5% | $6.3B+19.2% | $5.6B+2.2% | $5.4B+2.2% | $5.1B-3.4% | $5.3B-4.1% | $5.5B-4.1% |
| Current Liabilities | $3.0B+32.2% | $2.8B+44.5% | $3.2B+46.4% | $2.3B+35.7% | $2.2B+41.5% | $1.9B+21.9% | $2.2B+16.7% | $1.7B-14.4% |
| Non-Current Liabilities | $4.8B+50.7% | $4.8B+50.9% | $3.2B+0.7% | $3.2B-13.3% | $3.2B-14.6% | $3.2B-14.2% | $3.2B-14.5% | $3.7B+1.6% |
| Long-Term Debt | $4.0B+60.2% | $4.0B+60.3% | $2.5B+0.2% | $2.5B+0.1% | $2.5B+0.1% | $2.5B+0.1% | $2.5B+0.1% | $2.5B+0.2% |
| Total Equity | -$39.0Mn/m | $90.0M-72.0% | -$67.0M-348.1% | -$125.0Mn/m | -$22.0M-136.7% | $321.0M-2.1% | $27.0M-70.3% | -$41.0M-177.4% |
| Retained Earnings | $247.0M+23.5% | $386.0M-10.6% | $223.0M+125.3% | $190.0M+179.4% | $200.0M+545.2% | $432.0M+72.8% | $99.0M+191.2% | $68.0M-71.8% |
Not reported in any period shown, so not listed: Accounts Receivable.
CLX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $143.0M+53.8% | $330.0M+12.2% | -$122.0M-142.7% | $311.0M+72.8% | $93.0M-57.9% | $294.0M-13.5% | $286.0M+57.1% | $180.0M+17.6% |
| Depreciation & Amortization | $74.0M+32.1% | $78.0M+36.8% | $58.0M+5.5% | $55.0M+3.8% | $56.0M+3.7% | $57.0M-3.4% | $55.0M-5.2% | $53.0M-7.0% |
| Stock-Based Compensation | $9.0M-10.0% | N/A | $15.0M-37.5% | $24.0M-11.1% | $10.0M-23.1% | N/A | $24.0M | $27.0M |
| Capital Expenditures | $38.0M+5.6% | $86.0M+14.7% | $43.0M-18.9% | $42.0M-20.8% | $36.0M-7.7% | $75.0M-7.4% | $53.0M-3.6% | $53.0M+1.9% |
| Free Cash Flow | $105.0M+84.2% | $244.0M+11.4% | -$165.0M-170.8% | $269.0M+111.8% | $57.0M-68.7% | $219.0M-15.4% | $233.0M+83.5% | $127.0M+25.7% |
| Investing Cash Flow | -$35.0Mn/m | -$2.2Bn/m | -$43.0Mn/m | -$43.0Mn/m | -$34.0M-138.2% | -$76.0Mn/m | -$53.0Mn/m | -$54.0Mn/m |
| Financing Cash Flow | -$68.0Mn/m | $811.0Mn/m | $1.1Bn/m | -$210.0Mn/m | -$59.0Mn/m | -$279.0Mn/m | -$299.0Mn/m | -$109.0Mn/m |
| Dividends Paid | $151.0M0.0% | $150.0M0.0% | $150.0M0.0% | $151.0M0.0% | $151.0M0.0% | $150.0M+0.7% | $150.0M+1.4% | $151.0M+1.3% |
| Share Buybacks | $0-100.0% | $0-100.0% | $0n/m | $127.0M-15.3% | $129.0M+20.6% | $75.0Mn/m | $0n/m | $150.0Mn/m |
CLX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 40.4%-1.3pp | 41.3%-5.2pp | 43.2%-1.4pp | 43.2%-0.6pp | 41.7%-4.1pp | 46.5%0.0pp | 44.6%+2.4pp | 43.8%+0.3pp |
| Net Margin | 8.9%+3.3pp | 8.4%-8.3pp | 11.2%+0.1pp | 9.4%-2.1pp | 5.6%0.0pp | 16.7%+5.4pp | 11.2%+14.0pp | 11.5%+6.8pp |
| Return on Equity | N/A | 181.1%+77.7pp | N/A | N/A | N/A | 103.4%+37.6pp | 688.9%+744.9pp | N/A |
| Return on Assets | 2.2%+0.7pp | 2.1%-3.9pp | 2.9%-0.5pp | 2.8%-0.7pp | 1.5%-0.3pp | 6.0%+2.2pp | 3.4%+4.3pp | 3.5%+1.9pp |
| Current Ratio | 0.65-0.1x | 0.66-0.2x | 0.84+0.1x | 0.74-0.2x | 0.76-0.2x | 0.84-0.2x | 0.74-0.2x | 0.94+0.1x |
| Debt-to-Equity | N/A | 44.23+36.5x | N/A | N/A | N/A | 7.74+0.2x | 91.96+64.7x | N/A |
| Liabilities-to-Equity | N/A | 83.80+68.0x | N/A | N/A | N/A | 15.82-0.2x | 197.11+136.1x | N/A |
| Asset Turnover | 0.240.0x | 0.25-0.1x | 0.260.0x | 0.300.0x | 0.26-0.1x | 0.360.0x | 0.300.0x | 0.300.0x |
| FCF Margin | 5.5%+1.5pp | 12.5%+1.5pp | -9.9%-23.8pp | 16.1%+8.5pp | 4.0%-6.3pp | 11.0%-2.6pp | 14.0%+7.0pp | 7.5%+2.5pp |
Not reported in any period shown, so not listed: Operating Margin.
Note: The current ratio is below 1.0 (0.66), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Clorox Company CLX | FY2026 | $6.7B | $587.0M | 8.7% | $12.7B | 39/100 |
| Church & Dwight Co., Inc. CHD | FY2025 | $6.2B | $736.8M | 11.9% | $25.9B | 58/100 |
| The Estee Lauder Companies Inc. EL | FY2026 | $15.0B | $182.0M | 1.2% | $36.9B | 38/100 |
| Colgate-Palmolive Company CL | FY2025 | $20.4B | $2.1B | 10.5% | $77.0B | 61/100 |
| Kimberly-Clark Corp. KMB | FY2025 | $16.4B | $2.0B | 12.3% | $64.6B | 53/100 |
| e.l.f. Beauty, Inc. ELF | FY2026 | $1.6B | $26.3M | 1.6% | $6.4B | 61/100 |
Where Clorox Company Ranks
Frequently Asked Questions
Clorox Company (CLX) reported $6.7B in total revenue for fiscal year 2026. This represents a -5.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Clorox Company (CLX) revenue declined by 5.4% year-over-year, from $7.1B to $6.7B in fiscal year 2026.
Yes, Clorox Company (CLX) reported a net income of $677.0M over the trailing 12 months to September 30, 2026. In fiscal year 2026 it reported a net income of $587.0M, with a net profit margin of 8.7%.
As of fiscal year 2026, Clorox Company (CLX) had $143.0M in cash and equivalents against $4.0B in long-term debt.
Clorox Company (CLX) had a gross margin of 42.3% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.
Clorox Company (CLX) had a net profit margin of 8.7% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.
Yes, Clorox Company (CLX) paid $4.96 per share in dividends during fiscal year 2026.
Clorox Company (CLX) has a return on equity of 652.2% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
Clorox Company (CLX) generated $405.0M in free cash flow during fiscal year 2026. This represents a -46.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Clorox Company (CLX) generated $612.0M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.
Clorox Company (CLX) had $7.8B in total assets as of fiscal year 2026, including both current and long-term assets.
Clorox Company (CLX) invested $207.0M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
Clorox Company (CLX) invested $116.0M in research and development during fiscal year 2026.
Clorox Company (CLX) had a current ratio of 0.66 as of fiscal year 2026, which is below 1.0, which may suggest potential liquidity concerns.
Clorox Company (CLX) had a debt-to-equity ratio of 44.23 as of fiscal year 2026. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
Clorox Company (CLX) had a liabilities-to-equity ratio of 83.80 as of fiscal year 2026, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
Clorox Company (CLX) had a return on assets of 7.5% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
Clorox Company (CLX) trades at 18.8x earnings, its market capitalization divided by $677.0M net income, trailing 12 months to September 30, 2026. The market capitalization is $12.7B as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Clorox Company (CLX) trades at 1.8x sales, its market capitalization divided by $7.2B revenue, trailing 12 months to September 30, 2026. The market capitalization is $12.7B as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Clorox Company (CLX) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Clorox Company (CLX) has an earnings quality ratio of 1.04x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Clorox Company (CLX) scores 39 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.